Approval of First Oral GLP-1 for Weight Loss in UK

MedPal AI is selling hype, not results—no financials, just big promises and partnerships.

What the company is saying

MedPal AI plc is positioning itself as a first-mover in the UK private weight management market following the MHRA’s approval of oral semaglutide for weight loss. The company’s narrative is that this regulatory milestone, though granted to Novo Nordisk, creates a unique commercial window for its own private GLP-1 clinic, New Health, which is launching nationally. Management repeatedly frames the US launch of the same drug as a 'leading indicator' for UK demand, citing Novo Nordisk’s claim of three million US prescriptions in five months and emphasizing that over 80% of these were for patients new to GLP-1 therapy. The announcement stresses MedPal AI’s vertically integrated model—AI triage, human clinical oversight, and robotic dispensing—as a differentiator, suggesting this infrastructure is ready to meet anticipated demand. The company highlights an exclusive, zero-cost partnership with Epassi UK Limited, granting access to over 11 million employees, as a major distribution and marketing advantage. However, the announcement buries the fact that the drug is not yet available on the NHS and is still under NICE review, meaning the addressable market is currently limited to private payers. There is no mention of actual patient numbers, revenue, or operational milestones for MedPal AI, and the language is promotional, with frequent use of 'believes,' 'positions,' and 'ready,' but little in the way of hard evidence. Jason Drummond, the CEO, is the only notable individual identified with a clear institutional role, but no external institutional investors or partners are named. The messaging fits a classic pre-commercial biotech playbook: leverage a major regulatory event to imply imminent commercial upside, even though the approval is not for MedPal AI itself. Compared to prior communications (which are not available), there is no evidence of a shift in tone, but the current message is heavily forward-looking and aspirational.

What the data suggests

The only concrete numbers disclosed relate to external market context, not MedPal AI’s own performance. Novo Nordisk’s US prescription data—three million prescriptions in five months, with 80% new to GLP-1 therapy—demonstrates strong demand for oral semaglutide in the US, but there is no evidence that this will translate directly to the UK or to MedPal AI’s clinic. The Epassi partnership is quantified as access to 11 million employees, but there is no data on how many of these have engaged with MedPal AI’s app or services. There are no figures for MedPal AI’s revenue, profit, cash flow, prescription volumes, or patient sign-ups, nor any period-over-period comparisons or growth rates. The announcement does not provide any financial guidance, targets, or even qualitative statements about current commercial traction. Key operational metrics—such as the number of clinics, prescriptions filled, or conversion rates from the Epassi network—are entirely absent. The only operational fact is that MedPal AI runs a 24/7 AI-powered pharmacy, but there is no disclosure of its utilization or financial contribution. An independent analyst would conclude that, based on the numbers alone, there is no evidence of commercial success or even early traction for MedPal AI; all the disclosed data is either external or potential, not realised.

Analysis

The announcement adopts a positive tone, highlighting the regulatory approval of oral semaglutide in the UK and its perceived relevance to MedPal AI's private clinic launch. While several factual, realised claims are made (e.g., Novo Nordisk's US prescription volumes, partnership with Epassi, operation of an automated pharmacy), the core narrative inflates the likely impact on MedPal AI by drawing forward-looking conclusions about UK demand and the company's readiness. These projections are not substantiated by direct evidence of patient uptake, revenue, or operational milestones for MedPal AI itself. The language positions the company as uniquely prepared to capture demand, but this is not supported by measurable progress or financial data. There is no disclosure of large capital outlay or immediate earnings impact, and the execution distance is near-term given the imminent private launch, but the benefits remain unquantified.

Risk flags

• ●Operational risk is high because MedPal AI has not disclosed any data on patient uptake, prescription volumes, or revenue from its New Health clinic. Without evidence of actual demand, the business model remains unproven.
• ●Financial disclosure risk is acute: the announcement omits all core financial metrics, including revenue, profit, cash flow, and operating expenses. This lack of transparency makes it impossible to assess the company’s financial health or runway.
• ●Execution risk is significant, as the company must rapidly convert regulatory news into paying customers in a private-pay market. If uptake is slower than anticipated, the window of opportunity could close before meaningful revenue is generated.
• ●Forward-looking risk is substantial: the majority of the company’s claims are projections or beliefs about future demand, not realised outcomes. Investors are being asked to buy into a story, not a track record.
• ●Market access risk is present because the drug is not yet available on the NHS and remains under NICE review. The current addressable market is limited to private payers, which may be much smaller than implied.
• ●Pattern risk exists in the company’s reliance on external data (Novo Nordisk’s US launch) as a proxy for its own prospects. There is no evidence that US prescription trends will map directly to the UK private market or to MedPal AI’s offering.
• ●Capital intensity risk is flagged by the mention of a 24/7 AI-powered automated pharmacy and robotic dispensing technology. These are expensive to build and operate, and without scale, could become a financial drag.
• ●Key person risk is moderate: while Jason Drummond is named as CEO, there is no evidence of external institutional backing or notable third-party validation. The absence of such support increases the risk that the company is over-reliant on internal optimism.

Bottom line

For investors, this announcement is a classic example of a company leveraging a major regulatory event to generate excitement, but without providing any direct evidence of commercial traction or financial performance. The narrative is credible only insofar as the regulatory approval is real and the US market has shown strong demand for oral semaglutide, but there is no proof that MedPal AI is positioned to capture similar demand in the UK. The partnership with Epassi is potentially valuable, but without data on actual user engagement or conversion, it remains a theoretical asset. The absence of any financial disclosure—no revenue, no patient numbers, no operational milestones—means investors are being asked to take management’s word on faith. If MedPal AI wants to be taken seriously by sophisticated investors, it must disclose concrete metrics: patient sign-ups, prescription volumes, revenue, and cost structure. The next reporting period should be scrutinized for evidence of real uptake and financial progress; if these are not forthcoming, the investment case weakens considerably. At this stage, the announcement is a weak signal—worth monitoring, but not acting on—unless and until hard data is provided. The single most important takeaway is that MedPal AI’s story is all potential and no proof; until that changes, caution is warranted.

Announcement summary

(AIM: MPAL) MedPal AI plc announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted UK marketing authorisation for the first oral GLP-1 receptor agonist tablet (oral semaglutide) for weight loss and weight management. The approval, granted to Novo Nordisk, makes the tablet available on a prescription-only basis to adults who are obese (BMI of 30 or above) or overweight (BMI of 27 to 30). According to Novo Nordisk's announcement of 7 June 2026, US prescriptions for the tablet surpassed three million in just over five months, equivalent to approximately one prescription filled every five seconds. More than 80% of new pill prescriptions were for patients new to GLP-1 therapy. The approval is directly relevant to MedPal AI's private GLP-1 weight management clinic, New Health (new.co.uk), which is launching nationally. The tablet is not currently available on the NHS and remains subject to evaluation by the National Institute for Health and Care Excellence (NICE), meaning private provision is presently the only route to access. MedPal AI has a partnership agreement with Epassi UK Limited, granting exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms.

Disagree with this article?